TD Cowen reiterates Chewy stock Buy rating ahead of earnings By Investing.com

TD Cowen reiterated a Buy on Chewy with a $39 price target and forecasts Q4 fiscal 2025 revenue of $3.27B (+0.7% y/y), gross margin of 29.3% (vs 28.5% in Q4 FY24) and EBITDA of $158M (+26.9% y/y, ~2% below consensus). Multiple firms (Evercore $52 PT, Wolfe $44 PT, Piper Sandler $48 PT, William Blair Outperform) likewise remain positive ahead of the March 25 earnings release, though TD Cowen cut its PT from $48 to $39 citing macro headwinds and a slower pet-market recovery. The stock is down ~29% YTD and ~32% since Dec 10, 2024, leaving valuation at roughly 10x EV/EBITDA on TD Cowen’s FY26 estimates while the firm forecasts an 18% EBITDA CAGR for FY26–FY31.

Analysis

Chewy’s upcoming print is a classical catalyst vs. narrative test: the market is pricing a recovery story into a compressed multiple, so the near-term driver will be whether management can convert marketing and private-label investments into durable margin expansion rather than one-off channel mix moves. Second-order winners from a sustained margin recovery are not only Chewy but branded suppliers that agree to co-funded promotions and tighter assortment partnerships — expect pressure on mid‑tier national brands that can’t compete on promo economics, accelerating category consolidation in pet food and OTC pet care over 12–36 months.

Risks are concentrated and asymmetric: earnings can re-rate quickly on a quarter miss because the thesis depends on improving retention, rising ASPs and ad monetization simultaneously. Reversal triggers are higher CAC (paid media CPMs), promotional escalation from a deep-pocket competitor, or unexpected inventory write-downs; these manifest within 0–3 months and would compress near-term free cash flow. Over 2–5 years the story hinges on LTV/CAC stabilization — if LTV flattens, the multiple premium assumed by bullish models evaporates.

For portfolio construction, treat CHWY as a catalyst-driven trade with defined timeboxes rather than a perpetual core holding until LTV trends are visible. If the print shows unit economics improving, the re-rating should be front-loaded over the next 3–6 months; absent clear evidence, downside is faster than recovery because discretionary pet spend is elastic. Relative-value consideration: rotate opportunistically into higher conviction secular growers (e.g., SMCI/APP) if macro signals point to weaker consumer discretionary elasticity, since they offer asymmetric growth optionality versus a demand-sensitive retailer.

Key Decisions for Investors

• Long CHWY targeted catalyst trade (3–6 months): buy an out-of-the-money call spread to cap premium (size 2% notional). Thesis: earnings beat + credible LTV/CAC commentary → 2.5–3x option payoff. Stop-loss: lose full premium; take profits at 50–70% of max gain.
• Pair trade (6–12 months): long CHWY equity (1.5% NAV) / short AMZN or S&P exposure (delta-hedged ~0.8x) to isolate execution vs. market beta. Rationale: isolate idiosyncratic re-rating if Chewy shows margin improvement; target +30–50% vs market over 6–12 months, stop if CHWY underperforms index by 15% in 30 days.
• Event-protected income play (2–4 months): sell near-term covered calls on CHWY shares if already long, harvesting premium into the print; reduces breakeven by ~3–6% while capping upside. Use strikes ~10–15% above spot and roll only on sustained LTV evidence.
• Alternative allocation (12+ months): underweight discretionary retail and redeploy 1–2% NAV into SMCI or APP for secular growth exposure if macro signals weaken. Rationale: these names offer higher upside optionality and less sensitivity to short-term consumer spend shocks; target asymmetric upside >2x over 12–24 months.